Melane Sampson, Author at BioTuesdays

Developments

Silo partners with global CRO for preclinical study to advance homing peptide in MS

Silo Pharma (NASDAQ:SILO) has entered into an agreement with WuXi AppTec for a preclinical small animal study of SPU-16, a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS). Silo Pharma is...

August 7, 2024

Developments

Quoin Pharma plans clinical study of peeling skin syndrome in children

Quoin Pharmaceuticals (NASDAQ:QNRX) announced plans to initiate an investigator-led clinical study to evaluate the safety and efficacy of QRX003 in pediatric patients with peeling skin syndrome (PSS). The study will be...

August 6, 2024

Developments

Abivax achieves key enrollment milestone in Phase 3 trial of Obefazimod in UC

Abivax SA (Euronext Paris, NASDAQ:ABVX) reports reaching the 600-patient enrollment milestone for its Phase 3 ABTECT trial to evaluate its lead investigational drug candidate, Obefazimod, in patients with moderate-to...

August 6, 2024

Executive Moves

Carisma Therapeutics expands SAB with renowned KOLs

Carisma Therapeutics (NASDAQ:CARM) has appointed Drs. Scott Friedman and Ira Tabas to its scientific advisory board (SAB). “It is an honor to welcome Dr. Friedman and Dr. Tabas to our SAB,” said Steven...

August 6, 2024

Feature

Mauna Kea launches groundbreaking food-related IBS detection and treatment program

Mauna Kea Technologies (Euronext Growth:ALMKT), inventor of the world’s first and only real-time in vivo cellular imaging platform, Cellvizio, designed to deliver high-magnification visualization of cellular structures...

August 6, 2024

Developments

Anebulo announces NIDA grant for investigational treatment of acute cannabis-induced toxicities in children

Anebulo Pharmaceuticals (NASDAQ:ANEB) has been awarded the first tranche of a two-year, $1.9 million NIDA grant to develop intravenous selonabant for treating acute cannabis-induced toxicity, including CNS depression in...

July 22, 2024

Developments

Clearmind files additional U.S. patent application for MEAI to treat obesity

Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced it has filed an additional patent application with the USPTO for the novel proprietary composition of its MEAI compound for treating metabolic syndrome and obesity...

July 16, 2024

Developments

Alto Neuroscience announces Phase 2b enrollment completion in MDD study

Alto Neuroscience (NYSE:ANRO) announced the completion of enrollment in its Phase 2b study evaluating ALTO-100 in 300 adults with major depressive disorder (MDD) across 34 U.S. sites. The randomized, double-blind...

July 16, 2024

Feature

BerGenBio pioneering cutting-edge AXL therapies to fight aggressive diseases

BerGenBio (OSE:BGBIO) is developing a pipeline of transformative drugs targeting AXL as a cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections.

July 16, 2024

Developments

CMS unveils proposed reimbursement for TULSA to treat prostate disease

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that the U.S. Centers for Medicare and Medicaid Services has issued proposed rules establishing, for the first time, a Category 1 CPT code for the Transurethral...

July 12, 2024

Author - Melane Sampson

Silo partners with global CRO for preclinical study to advance homing peptide in MS

Quoin Pharma plans clinical study of peeling skin syndrome in children

Abivax achieves key enrollment milestone in Phase 3 trial of Obefazimod in UC

Carisma Therapeutics expands SAB with renowned KOLs

Mauna Kea launches groundbreaking food-related IBS detection and treatment program

Anebulo announces NIDA grant for investigational treatment of acute cannabis-induced toxicities in children

Clearmind files additional U.S. patent application for MEAI to treat obesity

Alto Neuroscience announces Phase 2b enrollment completion in MDD study

BerGenBio pioneering cutting-edge AXL therapies to fight aggressive diseases

CMS unveils proposed reimbursement for TULSA to treat prostate disease

Subscribe